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Abstract
Background: The Toll-like receptors (TLRs) mediate innate immunity to various pathogens. A
mutation (S180L) in the TLR downstream signal transducer TIRAP has recently been reported to
be common in Europeans and Africans and to roughly half the risks of heterogeneous infectious
diseases including malaria, tuberculosis, bacteremia, and invasive pneumococal disease in
heterozygous mutation carriers.
Methods: We assessed the TIRAP S180L variant by melting curve and RFLP analysis in 1095
delivering women from malaria-endemic Ghana, as well as in a further 1114 individuals participating
in case control studies on sepsis and leprosy in Germany, Turkey and Bangladesh.
Results: In Ghana, the TIRAP S180L polymorphism was virtually absent. In contrast, the mutation
was observed among 26.6%, 32.9% and 12% of German, Bangladesh and Turkish controls,
respectively. No significant association of the heterozygous genotype with sepsis or leprosy was
observed. Remarkably, homozygous TIRAP 180L tend to increase the risk of sepsis in the German
study (P = 0.04).
Conclusion: A broad protective effect of TIRAP S180L against infectious diseases per se is not
discernible.
Background
Almost sixty years ago, J. Haldane suggested that malaria
had selected hemoglobinopathies to high gene frequen-
cies in malaria-endemic areas due to the protection they
confer against this life-threatening disease [1]. This
"malaria hypothesis" is now the paradigm of evolutionary
selection by infectious diseases, and malaria is considered
the strongest known force in this regard [2]. Continuing
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this early finding a major goal of medical genetics during
the last two decades has been to unravel the influence of
host's genetics on susceptibility or pathogenesis of com-
mon diseases and find specific associations of human
genetic variations with these diseases [3,4].
While in case of malaria it is obvious that genetic varia-
tions of the erythrocyte – target of the malaria parasite
Plasmodium – can prevent or modulate disease, host pro-
teins involved in pathogen recognition and defense may
also be of pathophysiological importance in malaria [5]
and other infectious diseases. The discovery of the toll-like
receptor (TLR) system and of central signaling molecules
has improved our understanding of host-pathogen inter-
action in many infectious diseases [6]. Genetic variations
within this system have been found and some relate to
disease susceptibility and manifestation [7]. In vitro and in
vivo data point to TLRs -2, -4 and -9 to be central for Plas-
modium recognition and subsequent inflammatory host
responses [8-14]. The Toll-interleukin 1 receptor (TIR)
domain containing adaptor protein (TIRAP, also known
as Mal) mediates downstream signaling of TLR-2 and TLR-
4, eventually inducing pro-inflammatory responses [15].
Recently, an S180L single nucleotide polymorphism
(SNP) of TIRAP has been reported to diminish TLR-2 sig-
naling and to occur at a prevalence of some 30% among
healthy subjects in the UK and in 2–6% among individu-
als from West and East Africa. Heterozygosity for this SNP
has been claimed to confer protection against malaria and
severe malaria to an extent comparable to HbAS, and in
addition, to more than halve the risks of bacteremia and
tuberculosis in African populations [16]. In an attempt to
verify these broad and evolutionary important effects, we
screened for TIRAP  S180L in a Ghanaian population
exposed to holoendemic malaria transmission, and exam-
ined the role of the SNP in Caucasian and Asian patients
affected by sepsis or leprosy.
Methods
Study groups
We examined TIRAP S180L (rs8177374) in four groups of
individuals: i) 1095 delivering women were recruited at
the Presbyterian Mission Hospital in hyper- to holoen-
demic Agogo, Ashanti Region, Ghana in 2000 and in
2006. Diagnosis of placental Plasmodium falciparum infec-
tion by PCR and malariological indices of the majority of
women have been described elsewhere. Briefly, although
roughly half of the woman were infected by Plasmodium
falciparum as evidenced by specific PCR assays, only 4.5%
were febrile. Still, anaemia (hemoglobin < 11 g/dL) and
low birth weight (< 2500 g) occurred in 33% and 15%,
respectively, of woman with live singleton delivery
(median age: 25, range 15–47) [17]. ii) 223 patients with
sepsis (mean age: 61.4 ± 12.3, male/female: 138/85) and
188 controls without infection (mean age: 62.0 ± 12.5,
male/female: 122/66) were recruited at the intensive care
unit, Department of Surgery and Surgical Oncology, Rob-
ert-Rössle-Klinik, Charité – University Medicine Berlin,
Germany, as part of a retrospective case-control study on
the influence of different SNPs on sepsis following sur-
gery. Site of infection, relevant microorganisms detected,
type of surgery, and infectious complications were
recorded (Table 1). Sepsis was defined according to stand-
ard criteria [18]. iii) 263 leprosy patients (mean age, 31.1
± 15.6; male/female, 160/103), from north-west Bangla-
desh were randomly chosen from the COLEP study [19].
280 healthy controls were taken from the same study
(mean age: 25.2 ± 14.8, male/female: 140/131, data from
9 samples are not available). Patients were classified as
paucibacillary (n = 245) or multibacillary (n = 18) accord-
ing to the 1998 World Health Organization classification
for treatment purposes at the Rural Health Program Bang-
ladesh in 2002 and 2003 [20]. iiii) 60 leprosy patients
(mean age: 64.0 ± 12.6, male/female: 45/15, leproma-
tous: n = 50 and tuberculoid leprosy: n = 10) from Turkey,
all of Turkish descent, were recruited at the Leprosy Hos-
pital, Elazig, and Akdeniz University, Antalya, Turkey.
Diagnosis was based on clinical findings and laboratory
tests. Blood smears were analyzed from all patients, skin
biopsies were taken from all tuberculoid leprosy patients
and most of the lepromatous leprosy patients. M. leprae
was identified by the detection of acid-fast bacilli and spe-
cific histopathological changes. Differential diagnoses,
including granulomatous disease, syphilis, tuberculosis,
sarcoidosis, and deep fungal infection, were excluded by
clinical and laboratory criteria. One hundred asympto-
matic control subjects were recruited from the same cent-
ers and had neither a family history nor symptoms related
to leprosy (mean age: 43.7 ± 10.5, male/female: 45/55).
Ethical approval
The study protocols were reviewed and approved by the
Committee on Human Research Publication and Ethics,
School of Medical Sciences, University for Science and
Technology, Kumasi, Ghana, and by the human subject
review committees at Humboldt-University Berlin, Ger-
many, and Akdeniz University, Antalya, Turkey, and the
institutional guidelines were followed in conducting this
study. For the Bangladesh study, written approval was
granted by the Ethical Review Committee of Bangladesh
Medical Research Council (BMRC/ERC/2001–2004/799
and BMRC/ERC/2004–2007/120.
Sample size calculations
For this exploratory survey, no definite sample size calcu-
lation was performed. However, considering published
average prevalences of TIRAP S180L of 30% in Cauca-
sians, Asians and 4% in Africans [16], and 33% in Bangla-
desh, this study had a power of 80% at a 95% confidence
level to display risk reductions (odds ratios) of 0.27, 0.50,BMC Medical Genetics 2009, 10:65 http://www.biomedcentral.com/1471-2350/10/65
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0.22, and 0.56 for malaria, sepsis, leprosy (Turkey) and
leprosy (Bangladesh), respectively.
Genotyping
DNA was extracted from blood by standard techniques.
Genotyping for TIRAP S180L was carried out by melting
curve analysis employing the Lightcycler 480 device
(Roche Diagnostics, Mannheim, Germany) using the fol-
lowing primers and probes: sense primer: GCCAG-
GCACTGAGCAGTAGT, antisense primer:
GTGGGTAGGCAGC-TCTTCTG, anchor probe: Red640-
GATGGTGCAGCCCTCGGCCCC, and sensor probe:
AGGCCCAACAGCAGGG-FL. The melting peaks are at
53°C and 62°C for the wildtype and the mutated
sequences, respectively. Due to secondary structures and
allele biased amplification within the region of this SNP,
analysis of heterozygous genotypes may sometimes result
in false homozygous results. Therefore, all mutated sam-
ples were reanalysed by conventional RFLP method
described by Khor et al. [16]. Genomic DNA was ampli-
fied with following primers: CTCCAGGGGCCGAG-
GGCTGCACCATCCCCATGCTG and TACT-
GTAGCTGAATCCCGTTCC. The resulting PCR product
was digested with BstXI and analysed by gel electrophore-
sis.
Statistical analysis
Comparison of proportions of heterozygous and wild
type individuals was done by χ2 or Fisher's exact test, as
applicable.
Results
The prevalence of TIRAP S180L among German controls
of 26.6% (allele frequency, 19.2%) closely matched the
Table 1: Detailed description of sepsis patients
Cohort (n = 223) Characteristic aSer/Ser
(n = 170)
aSer/Leu
(n = 43)
aLeu/Leu
(n = 10)
No (%) of patients Co-existing diseases
103 (46.2) Arterial hypertension 77 (74.8) 22 (21.4) 4 (3.9)
82 (36.8) Myocardial disease 67 (81.7) 14 (17.0) 1 (1.2)
53 (23.8) Diabetes 35 (66.0) 14 (26.0) 4 (7.5)
52 (23.3) Lung pathology 44 (84.6) 6 (11.5) 2 (3.8)
16 (7.2) Renal pathology 11 (68.8) 4 (25.0) 1 (6.3)
No (%) of patients Type of surgery
76 (34.1) Upper-GI resection 58 (76.3) 16 (21.1) 2 (2.6)
62 (27.8) Colorectal resection 46 (74.2) 12 (19.4) 4 (6.5)
50 (22.4) bOther abdominal 37 (74.0) 10 (20.0) 3 (6.0)
15 (6.7) Thoracic 11 (73.4) 3 (20.0) 1 (6.7)
20 (9.0) Limb and others 18 (90.0) 2 (10.0) - -
No (%) of infections Type of Infection
92 (41.3) Pneumonia 68 (73.9) 20 (21.7) 4 (4.3)
38 (17.0) Peritonitis 27 (71.1) 9 (23.7) 2 (5.3)
65 (29.2) Abscess 52 (80.0) 10 (15.4) 3 (4.6)
4 (1.8) Urinary tract infections 3 (75.0) 1 (25.0) - -
24 (10.8) Other 20 (83.3) 3 (12.5) 1 (4.2)
No (%) of infectionsc Microorganisms
129 (57.9) Gram-negative 97 (75.2) 25 (19.4) 7 (5.4)
83 (37.2) Gram-positive 60 (72.3) 18 (21.7) 5 (6.0)
15 (6.7) Fungi 13 (86.7) 2 (13.3) - -
31 (13.9) Polymicrobial 19 (61.3) 9 (29.0) 3 (9.8)
24 (10.8) Clinically diagnosed 15 (62.5) 8 (33.3) 1 (4.2)
No (%) of patients Morbidity and Mortality
114 (51.1) Sepsis without organ dysfunction 90 (78.9) 22 (19.3) 2 (1.8)
109 (48.9) Severe sepsis and septic shock 80 (73.4) 21 (19.3) 8 (7.3)d
28 (12.6) Mortality ICU 21 (75.0) 6 (21.4) 1 (3.6)
34 (15.3) Mortality hospital 26 (76.5) 7 (20.6) 1 (2.9)
aSer/Ser indicates wildtype, Ser/Leu indicates heterozygous and Leu/Leu indicates homozygous individuals. bOther abdominal operations: pancreas-, 
liver- and multiple visceral organ resection. cNumbers might exceed total number of infections due to multiple or no detections. dIncreased 
frequency of Leu/Leu in patients with severe sepsis and septic shock compared to patients without organ dysfunction, 7.3 versus 1.8%, P = 0.1. No 
significant differences were observed by comparing patient characteristics. Abbreviation: ICU: Intensive Care Unit.BMC Medical Genetics 2009, 10:65 http://www.biomedcentral.com/1471-2350/10/65
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reported figure from the United Kingdom [16]. Surpris-
ingly, however, we detected the heterozygous TIRAP
S180L variant in only one (0.1%) out of 1095 individuals
from malaria holoendemic Ghana. This asymptomatic
woman had a placental P. falciparum infection with a
mean of 28 parasites/microscopic high power field, and
prematurely delivered a child of low birth weight. The
mere absence of the SNP in more than 500 P. falciparum
non-infected women rendered statistical analysis mean-
ingless (Table 2).
In the German sepsis study, the heterozygous TIRAP
S180L genotype was frequent but there was no significant
association with the risk of developing sepsis. Neverthe-
less, heterozygosity was slightly more frequent in controls
than in patients, 25.5% versus 19.3%, respectively (P =
0.19, Table 2), potentially indicating some advantage
when the heterozygous genotype was present. In contrast,
the homozygous TIRAP 180L genotype was significantly
more frequent in patients, (4.5 versus 1.1%, P = 0.04,
Table 2), indicating this genotype to potentially be a risk
factor for developing sepsis. This is also being reflected by
a trend showing a slightly increased frequency of the
homozygous  TIRAP 180L within the patient group of
severe sepsis and septic shock compared to septic patients
without organ dysfunction (7.4 versus 1.7%, P  = 0.1,
Table 1).
Both leprosy studies showed no significant association
either of heterozygosity or homozygosity with leprosy
(Table 2). Again, we found a slightly enhanced frequency
of heterozygosity in controls from Bangladesh compared
to leprosy patients, 31.4% versus 25.9% (P = 0.22), also
potentially indicating some degree of advantage of the
heterozygous mutation for leprosy. The small study from
Turkey showed controversial results. We observed hetero-
zygous TIRAP S180L in 11% of control individuals, but
more frequently, 22%, in leprosy patients (Table 2). How-
ever, the sample number of this study is too low for signif-
icant conclusions.
Discussion
We here report the virtual absence of a putatively malaria-
protective SNP in an area of holoendemic malaria trans-
mission in West Africa. This not only contrasts the pub-
lished prevalence among African populations of 2–6%
[16], also, and more importantly, it argues against clini-
cal-epidemiological relevance in malaria and against the
hypothesis that malaria has exerted significant positive
selective pressure on the presence of this SNP. According
to Haldane's malaria hypothesis [1,2], higher frequencies
of this SNP than reported and observed here should be
expected in highly malaria-endemic areas considering the
postulated protective effect against this disease of 42–96%
[16]. We are at loss to explain the discrepancy between the
reported prevalences of 5.9 and 3.4% among control pop-
ulations in such distantly located African countries as The
Gambia and Kenya and the 0.1% we found in Ghana.
Nevertheless, the latter figure – particularly when facing
the 15–30% in Caucasians – strongly argues against an
expected positive selection of a malaria-protective trait in
Africa. The absence of homozygosity for TIRAP 180L in
the African studies could suggest a state of balanced poly-
morphism due to a yet unknown disadvantage in
homozygotes and acting against relevant allele frequen-
cies. A homozygous disadvantage has been claimed for
Caucasians with respect to a slightly increased risk for
invasive pneumococcal disease and pneumococcal
empyema [16]. One theoretical limitation of the present
study is that we examined predominantly asymptomatic
Table 2: Frequency of the TIRAP-S180L variant in different populations
No. of individuals with genotype (%)
Population and disease No. Variant
Allele Frequency (%)
Ser/Ser Ser/Leu Leu/Leu P valuea
Ghana, delivering women
P. falciparum positive 541 0.1 540 (99.8) 1 (0.2) 0 (0) 0.49
P. falciparum negative 554 0 554 (100) 0 (0) 0 (0)
Germany
Sepsis patients 223 18.1 170 (76.2) 43 (19.3) 10 (4.5) 0.19
Controls 188 19.2 138 (74.4) 48 (25.5) 2 (1.1)b
Bangladesh
Leprosy patients 263 16.3 186 (70.7) 68 (25.9) 9 (3.4) 0.22
Controls 280 17.2 188 (67.1) 88 (31.5) 4 (1.4)
Turkey 0.11
Leprosy patients 60 10.8 47 (78) 13 (21) 0 (0)
Controls 100 6.5 88 (88) 11 (11) 1 (1)
a Comparison of proportions of heterozygotes and wildtype individuals by χ2 or Fisher's exact test, as applicable. bP value = 0.04, for comparison of 
homozygous 180L individuals and other individuals. Differences of allele frequencies are not significant.BMC Medical Genetics 2009, 10:65 http://www.biomedcentral.com/1471-2350/10/65
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women with or without placental P. falciparum infection.
Thus, potential protective features of the SNP could be
missed in individuals with non-severe malaria. However,
in The Gambia the risk reductions in terms of severe
malaria and "general malaria" were very similar [16]. Ulti-
mately, the extremely low prevalence of heterozygous
TIRAP  S180L in Ghana, where malaria endemicity is
among the highest in the world argues against attempts to
replicate its putatively protective effect: Given the
observed prevalence of heterozygosity of 0.1%, a study
able to confirm the reported risk reduction would need to
comprise several tens of thousands of individuals to have
sufficient statistical power. This, in turn, is even another
argument against the presumed clinical relevance of this
mutation in Africa.
Heterozygosity for TIRAP S180L has been suggested to be
protective not only against malaria but also against bacte-
rial infections including invasive pneumococcal disease,
pneumococcal empyema, overall and pneumococcal bac-
teremia, and tuberculosis [16]. In our study populations
from Germany, Bangladesh, and Turkey we found allele
frequencies of 19, 17, and 6.5%, respectively. However,
we only found very limited evidence for heterozygosity
being protective in both, sepsis and leprosy patients. Like-
wise, within the subgroup of sepsis patients suffering from
pneumonia no significant protection of heterozygosity
could be observed (Table 1). In the sepsis study, the pro-
portion of heterozygous TIRAP S180L genotype seem to
be influenced by co-existing diseases such as Diabetes and
renal pathology, however, there is no significant differ-
ence (Table 1). In contrast, we found at borderline signif-
icance an increased frequency of homozygosity in sepsis
patients (p = 0.04, Table 2). This is in line with the data
reported by Khor et al. [16], who also showed an
increased, but not significant, frequency of homozygosity
in invasive pneumococcal disease and pneumococcal
empyema. However, larger studies are needed to verify
whether heterozygosity is protective or homozygosity is a
risk factor. Remarkably also, in a recent study from
Ghana, Russia and Indonesia, TIRAP S180L also failed to
show any association of heterozygosity with tuberculosis
in any population. Of note, this study also found a very
low allele frequency for the TIRAP S180L of only 0.08% in
Ghana [21].
Conclusion
While the TLR system has been shown to be critically
involved in susceptibility to and manifestation of malaria,
we found a very low frequency of the S180L mutation in
the TLR downstream mediator TIRAP in a highly endemic
region arguing against a major role of this SNP in malaria.
In our study populations with a relative high prevalence
of the TIRAP S180L, we found a trend but no significant
protection of heterozygosity in sepsis and leprosy. In con-
trast, in sepsis TIRAP 180L homozygosity appears to be a
risk factor for disease. Taking together our data and those
of Khor et al. [16], we suggest that there might be a slight
protective effect of heterozygous TIRAP S180L in several
diseases. At the same time homozygous TIRAP  180L
appears to be a risk factor for the same diseases. The spe-
cific role of TIRAP S180L needs further investigation.
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